JP7421500B2 - 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法 - Google Patents

抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法 Download PDF

Info

Publication number
JP7421500B2
JP7421500B2 JP2020564482A JP2020564482A JP7421500B2 JP 7421500 B2 JP7421500 B2 JP 7421500B2 JP 2020564482 A JP2020564482 A JP 2020564482A JP 2020564482 A JP2020564482 A JP 2020564482A JP 7421500 B2 JP7421500 B2 JP 7421500B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
ifn
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525236A5 (https=
JP2021525236A (ja
JPWO2019220412A5 (https=
Inventor
セサロニ，マッテオ
ジョーダン，ジャラット
ロザ，マシュー
セリディ，ロクメーン
Original Assignee
ヤンセン バイオテツク，インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン バイオテツク，インコーポレーテツド filed Critical ヤンセン バイオテツク，インコーポレーテツド
Publication of JP2021525236A publication Critical patent/JP2021525236A/ja
Publication of JP2021525236A5 publication Critical patent/JP2021525236A5/ja
Publication of JPWO2019220412A5 publication Critical patent/JPWO2019220412A5/ja
Application granted granted Critical
Publication of JP7421500B2 publication Critical patent/JP7421500B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N29/00—Investigating or analysing materials by the use of ultrasonic, sonic or infrasonic waves; Visualisation of the interior of objects by transmitting ultrasonic or sonic waves through the object
    • G01N29/44—Processing the detected response signal, e.g. electronic circuits specially adapted therefor
    • G01N29/4409—Processing the detected response signal, e.g. electronic circuits specially adapted therefor by comparison
    • G01N29/4418—Processing the detected response signal, e.g. electronic circuits specially adapted therefor by comparison with a model, e.g. best-fit, regression analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Rehabilitation Therapy (AREA)
JP2020564482A 2018-05-18 2019-05-17 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法 Active JP7421500B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862673426P 2018-05-18 2018-05-18
US62/673,426 2018-05-18
PCT/IB2019/054104 WO2019220412A2 (en) 2018-05-18 2019-05-17 Safe and effective method of treating lupus with anti-il12/il23 antibody

Publications (4)

Publication Number Publication Date
JP2021525236A JP2021525236A (ja) 2021-09-24
JP2021525236A5 JP2021525236A5 (https=) 2022-05-25
JPWO2019220412A5 JPWO2019220412A5 (https=) 2022-05-25
JP7421500B2 true JP7421500B2 (ja) 2024-01-24

Family

ID=68532802

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564482A Active JP7421500B2 (ja) 2018-05-18 2019-05-17 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法

Country Status (4)

Country Link
US (2) US11578124B2 (https=)
EP (1) EP3793521A4 (https=)
JP (1) JP7421500B2 (https=)
WO (1) WO2019220412A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
US20200197517A1 (en) * 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
AU2020386669A1 (en) * 2019-11-19 2022-06-02 Novartis Ag Methods of treating Lupus Nephritis using interleukin-17 (IL-17) antagonists
CN113035299B (zh) * 2021-04-02 2022-03-29 上海药明津石医药科技有限公司 分中心推荐方法、装置、计算机设备和存储介质
WO2023057369A2 (en) * 2021-10-04 2023-04-13 Astrazeneca Ab Treatment of lupus
WO2024100139A1 (en) * 2022-11-09 2024-05-16 Merck Patent Gmbh Use of ifn-i activity as a biomarker for tlr inhibitor treatment
WO2024102200A1 (en) * 2022-11-10 2024-05-16 Ampel Biosolutions, Llc Methods and systems for evaluation of lupus based on ancestry-associated molecular pathways
WO2024129960A2 (en) * 2022-12-16 2024-06-20 Vetmab Biosciences, Inc. Anti-il23 and anti-tnfα antibodies: compositions and veterinary use
AU2024301395A1 (en) * 2023-07-21 2025-12-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of il-12 related biomarkers and il-12 specific blocking antibodies for the treatment of an autoimmune disease
WO2025143577A1 (ko) * 2023-12-28 2025-07-03 아주대학교 산학협력단 전신 홍반성 루푸스 플레어 예측용 바이오마커
US12494266B1 (en) * 2024-06-10 2025-12-09 Recursion Pharmaceuticals, Inc. Utilizing a clinical-phenomics causal discovery framework to generate causal discovery predictions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5811523A (en) 1988-11-10 1998-09-22 Trinchieri; Giorgio Antibodies to natural killer stimulatory factor
CA2441636A1 (en) 1988-11-10 1990-05-10 The Wistar Institute Of Anatomy And Biology Natural killer stimulatory factor
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
ATE366311T1 (de) 1989-12-22 2007-07-15 Hoffmann La Roche Zytotoxischer lymphozyten-reifefaktor 35kd untereinheit und monoklonale antikörper spezifisch dafür
DE4315127A1 (de) 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
CA2125763C (en) 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
ZA95960B (en) 1994-03-14 1995-10-10 Genetics Inst Use of interleukin-12 antagonists in the treatment of autoimmune diseases
WO1995029239A2 (en) 1994-04-22 1995-11-02 Corixa Corporation Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5853697A (en) 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
AU6150498A (en) 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
WO1999037682A2 (en) 1998-01-23 1999-07-29 F.Hoffmann-La Roche Ag Antibodies against human il-12
JP3579355B2 (ja) 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
SI2168984T1 (sl) 1999-03-25 2012-12-31 Abbott Gmbh & Co. Kg Človeška protitelesa za vezavo IL-12 in postopki izdelave
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
AU7127600A (en) 1999-09-17 2001-04-17 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20160279239A1 (en) * 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
SG158150A1 (en) 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
US20070238094A1 (en) * 2005-12-09 2007-10-11 Baylor Research Institute Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis
EP2205276A4 (en) 2007-09-28 2012-08-15 Janssen Biotech Inc ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
CA2819538A1 (en) * 2010-11-30 2012-06-07 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle.
EP2729174A1 (en) * 2011-07-08 2014-05-14 Merck Sharp & Dohme Corp. Il-23 antagonists for treatment or prevention of skin rash associated with treatment with p13k/akt pathway inhibitors
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
US9809854B2 (en) * 2012-11-15 2017-11-07 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus
US20170002060A1 (en) 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
EP3143399A1 (en) * 2014-05-12 2017-03-22 Biogen MA Inc. Biomarkers predictive of lupus progression and uses thereof
US11643460B2 (en) 2014-10-28 2023-05-09 Staley Brod Administration of an anti-interleukin 12/23 antibody for treatment of autoimmune disease
JP6909208B2 (ja) * 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
MA45122A (fr) 2016-05-24 2019-04-10 Constellation Pharmaceuticals Inc Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017172771A2 (en) 2016-03-29 2017-10-05 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
History of Change for Study:NCT02268409, [online], 2018-MAY-04, ClinicalTrials.govarchive, NCT ID:NCT03517722 [Retrieved on 2023-APR-18], Retrievedfrom the internet，<URL:https://clinicaltrials.gov/ct2/history/NCT03517722?V_1=View#StudyPageTop>

Also Published As

Publication number Publication date
US20230279097A1 (en) 2023-09-07
WO2019220412A3 (en) 2020-05-07
WO2019220412A2 (en) 2019-11-21
JP2021525236A (ja) 2021-09-24
US20190352388A1 (en) 2019-11-21
EP3793521A4 (en) 2022-02-23
US11578124B2 (en) 2023-02-14
EP3793521A2 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
JP7421500B2 (ja) 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
JP7695077B2 (ja) 抗ｉｌ１２／ｉｌ２３抗体でループスを治療する安全かつ有効な方法
JP7359845B2 (ja) 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
JP2023052036A5 (https=)
JP2019514858A (ja) 抗ｉｌ１２及び／又は−２３抗体の増加した間隔投与による乾癬の処置
JP7516250B2 (ja) 抗ｉｌ－２３特異的抗体を用いたクローン病の治療方法
JP2020500152A (ja) 抗ｉｌ２３特異的抗体で乾癬を治療する安全かつ有効な方法
JP2026031932A (ja) 抗ｉｌ２３特異的抗体で乾癬性関節炎を治療する安全かつ有効な方法
US20230277665A1 (en) Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
JP2020502261A (ja) 抗ｉｌ２３特異的抗体で乾癬を治療する方法
JP2024510588A (ja) 抗ｉｌ２３特異的抗体による、ｔｎｆ療法に対する不十分な応答を有する乾癬性関節炎患者を治療する方法
JP2024038223A (ja) 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
JPWO2020065532A5 (https=)
JP2023524125A (ja) 抗ｉｌ２３特異的抗体によるクローン病の治療方法
JP2023514567A (ja) 抗ｉｌ１２／ｉｌ２３抗体で潰瘍性大腸炎を治療する安全かつ有効な方法
JP2024541946A (ja) 抗ｉｌ２３特異的抗体を用いてクローン病を治療する方法
EP4424381A2 (en) Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
KR20240107176A (ko) 항-il23 특이적 항체로 크론병을 치료하는 방법
JP2025500882A (ja) 全身性硬化症の治療のためのｉｌ－２３特異的抗体
EA052756B1 (ru) Способы лечения болезни крона с использованием специфического антитела к ил-23

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220517

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230425

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240112

R150 Certificate of patent or registration of utility model

Ref document number: 7421500

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150